BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

First patient dosed at lead trial site, Southside Cancer Care. Phase 1 trial to determine safety ... it was found to have an effect in a range of solid and blood-based cancers including breast ...

particularly in the context of solid phase peptide synthesis (SPPS), the webinar introduces a transformative approach toward achieving sustainability. This work combines, for the first time, the use ...

Kris Licht, chief executive officer, said: “We delivered a solid first quarter driven by Core Reckitt with continued strong growth in Emerging Markets. “We continue to execute against our ...

Researchers at the University of Tsukuba, Japan, have developed a method for synthesizing polyaniline—a conductive polymer exhibiting golden luster—marking the first successful attempt globally.

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy. The first patient has been enrolled in the phase ...

today announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors. ALTA3263 is an oral KRAS-selective inhibitor specifically ...

The closing of the acquisition is subject to certain conditions and expected in the first half of 2025 ... s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis ...

Being the first and only certified peptide clinic in northern Louisiana, physicians must have extensive training. Peptides are little mini proteins. They’re naturally found in the body and, as we age, ...

New approach to harness cytokine biology to treat cancer patients advances to the clinic First patient ... with advanced solid tumors Compugen responsible for running the Phase 1 trial This ...